{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-062194","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.996296+00:00","generated_at":"2026-05-18T08:54:39.676946+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs","bullets":["Workforce reduction of ~50% and halting of all non-chronic urticaria programs.","Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.","CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.","Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.","Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-062194","json":"https://secwatch.observer/filing/0001213900-25-062194.json","markdown":"https://secwatch.observer/filing/0001213900-25-062194.md","text":"https://secwatch.observer/filing/0001213900-25-062194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/0001213900-25-062194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/ea0248394-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:54:39.676946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efeafcbb248d0796cb057accdd1cd1763b58f492","claim":"Jasper Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million - $2.2 million affecting the Company (approximately 50%).","evidence_excerpt":"in chronic urticaria and is halting other clinical and preclinical programs along with the reduction in workforce. The Company estimates that it will incur approximately $1.8 million - $2.2 million of cash expenditures in connection with the corporate reorganization, which relate to severance pay, and are expected to be incurred through the quarter ending","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/0001213900-25-062194-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.8 million - $2.2 million"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"approximately 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}